Literature DB >> 12009502

Heparin attenuates cytotoxic and inflammatory activity of Alzheimer amyloid-beta in vitro.

Luigi Bergamaschini1, Cesare Donarini, Emanuela Rossi, Ada De Luigi, Carlo Vergani, Maria Grazia De Simoni.   

Abstract

Amyloid-beta protein (Abeta) is implicated in the pathogenesis of Alzheimer's disease because of its neurotoxicity and the ability to trigger local inflammation. Compounds that interact with the amino acids of the N-terminal region or interfere with aggregation can reduce the Abeta biologic activity. We evaluated the effect of heparin on Abeta (1-42) neurotoxicity and on its ability to activate complement and contact system. On differentiated PC12 cells, a reliable model of neuronal cells, heparin at the doses of 10 and 20 microg/ml significantly counteracted Abeta cytotoxicity as assessed by measuring MTT conversion. We then explored the effect of heparin on Abeta (1-42)-induced complement and contact system activation. Abeta (1-42) was incubated with heparin in presence of normal plasma as the source of complement and contact system factors. Heparin reduced, in a dose-dependent manner, complement and contact system activation, assessed by measuring the degree of C4 and high molecular weight kininogen cleavage. The present data show that heparin can attenuate neurotoxic and pro-inflammatory activity of Abeta and suggest that this drug could represent a new strategy to reduce the progressive neurodegeneration in AD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12009502     DOI: 10.1016/s0197-4580(02)00003-9

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  15 in total

1.  Potential beneficial effects of low molecular weight heparin on cognitive impairment in elderly patients on haemodialysis.

Authors:  Milenka Sain; Vedran Kovacic; Josipa Radic; Dragan Ljutic; Ivo Jelicic
Journal:  Drugs Aging       Date:  2012-01-01       Impact factor: 3.923

Review 2.  Sulfated glycosaminoglycans in protein aggregation diseases.

Authors:  Kazuchika Nishitsuji; Kenji Uchimura
Journal:  Glycoconj J       Date:  2017-04-11       Impact factor: 2.916

3.  Heparan sulphate proteoglycan and the low-density lipoprotein receptor-related protein 1 constitute major pathways for neuronal amyloid-beta uptake.

Authors:  Takahisa Kanekiyo; Juan Zhang; Qiang Liu; Chia-Chen Liu; Lijuan Zhang; Guojun Bu
Journal:  J Neurosci       Date:  2011-02-02       Impact factor: 6.167

4.  Neuroprotective Activities of Heparin, Heparinase III, and Hyaluronic Acid on the Aβ42-Treated Forebrain Spheroids Derived from Human Stem Cells.

Authors:  Julie Bejoy; Liqing Song; Zhe Wang; Qing-Xiang Sang; Yi Zhou; Yan Li
Journal:  ACS Biomater Sci Eng       Date:  2018-06-28

Review 5.  The chemical neurobiology of carbohydrates.

Authors:  Heather E Murrey; Linda C Hsieh-Wilson
Journal:  Chem Rev       Date:  2008-05-02       Impact factor: 60.622

6.  Mechanism of amylin fibrillization enhancement by heparin.

Authors:  Suman Jha; Sharadrao M Patil; Jason Gibson; Craig E Nelson; Nathan N Alder; Andrei T Alexandrescu
Journal:  J Biol Chem       Date:  2011-05-09       Impact factor: 5.157

7.  Heparin Attenuates the Expression of TNFalpha-induced Cerebral Endothelial Cell Adhesion Molecule.

Authors:  Jeong Ho Lee; Chul Hoon Kim; Gi Ho Seo; Jinu Lee; Joo Hee Kim; Dong Goo Kim; Young Soo Ahn
Journal:  Korean J Physiol Pharmacol       Date:  2008-10-31       Impact factor: 2.016

8.  Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer's disease.

Authors:  Chia-Chen Liu; Na Zhao; Yu Yamaguchi; John R Cirrito; Takahisa Kanekiyo; David M Holtzman; Guojun Bu
Journal:  Sci Transl Med       Date:  2016-03-30       Impact factor: 17.956

Review 9.  Heparan sulfate S-domains and extracellular sulfatases (Sulfs): their possible roles in protein aggregation diseases.

Authors:  Kazuchika Nishitsuji
Journal:  Glycoconj J       Date:  2018-07-12       Impact factor: 2.916

Review 10.  Heparin oligosaccharides as potential therapeutic agents in senile dementia.

Authors:  Qing Ma; Umberto Cornelli; Israel Hanin; Walter P Jeske; Robert J Linhardt; Jeanine M Walenga; Jawed Fareed; John M Lee
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.